Moderna's (NASDAQ: MRNA) lucrative relationship with the U.S. government took another big step forward on Sunday. The Biomedical Advanced Research and Development Authority (BARDA) amended its contract with the clinical-stage biotechnology company for an additional commitment of up to $472 million.
In April, BARDA agreed to a commitment of up to $483 million to support the advancement of Moderna's coronavirus vaccine candidate, mRNA-1273, from phase 1 trials through FDA licensure. The total value of the award was boosted to $955 million to support a 30,000 person phase 3 trial, which is a lot more participants than originally intended.
Image source: Getty Images.